Roche Says Phase 3 Studies for Alzheimer's Drug Failed to Meet Primary Endpoints -- Update
November 14 2022 - 2:40AM
Dow Jones News
By Pierre Bertrand
Roche Holding AG said Monday that Phase 3 Graduate studies of
gantenerumab, for treatment of early Alzheimer's disease, failed to
meet its primary endpoints.
The Swiss pharma company said the drug failed to slow patients'
clinical decline, adding that the drug's removal of beta-amyloid, a
protein that builds up to make plaques in the brains of people with
Alzheimer's disease, was lower than expected.
Nearly 2,000 people in 30 countries participated in the studies.
Although patients treated with the drug showed a slowing of
clinical decline in Graduate I and Graduate II tests by 8% and 6%,
respectively, when compared with those given placebos, the results
weren't statistically significant, Roche said.
The company said it would keep working on novel diagnostics and
treatments for Alzheimer's and that it would present the data at
the Clinical Trials on Alzheimer's Disease Conference on Nov.
30.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 14, 2022 02:25 ET (07:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024
